The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Oct 2013 08:48

Adept Telecom: Northland Capital revises target price from 145p to 165p and reiterates a buy recommendation.Aggreko: JP Morgan reduces target price from 1620p to 1505p, while its neutral recommendation remains unchanged. UBS cuts target price from 1610p to 1555p keeping its neutral rating.APR Energy: Investec raises target price from 900p to 1150p and stays with its hold recommendation.ARM Holdings: RBC Capital moves target price from 1050p to 1080p and retains an outperform rating.Barratt Developments: Liberum Capital ups target price from 374p to 387p and maintains a buy recommendation.Bellway: Liberum Capital takes target price from 1700p to 1760p and retains its buy recommendation.Berkeley Group: Liberum Capital raises target price from 2400p to 2634p, while reiterating a hold recommendation.Blur Group: Liberum Capital raises target price from 400p to 700p and stays with its buy recommendation.Bovis Homes Group: Liberum Capital increases target price from 791p to 911p upgrading to buy.Braemer Shipping Services: Westhouse Securities takes target price from 515p to 590p and reiterates an add rating.BT Group: Bank of America ups target price from 350p to 400p retaining a buy recommendation.Coca-Cola HBC: Nomura reduces target price from 1600p to 1500p and downgrades from neutral to reduce.EMIS Group: N+1 Singer takes target price to 748p upgrading from hold to buy.Europa Oil & Gas: Northland Capital shifts target price from 17.60p to 19.70p and stays with its buy recommendation.Genel Energy: RBC Capital revises target price from 1100p to 1300p and maintains an outperform rating.Getech: WH Ireland shifts target price from 86p to 92p staying with its buy recommendation.GlaxoSmithKline: Barclays lowers target price from 1555p to 1545p and retains an equal-weight rating.Halfords Group: Investec ups target price from 400p to 460p and maintains its buy recommendation.HSBC Holdings: Goldman Sachs cuts target price from 950p to 900p, while reiterating its strong buy recommendation.ITV: Berenberg raises target price from 91p to 155p, but downgrades from hold to sell.Kirkland Lake Gold: Investec cuts target price from 377p to 353p, while its buy recommendation is kept.Lloyds Banking Group: Goldman Sachs shifts target price from 75p to 76p and maintains a neutral rating. Numis downgrades to hold with a target price of 85p.Microgen: Investec lowers target price from 147p to 143p and keeps a hold recommendation. Westhouse Securities cuts target price from 155p to 145p, while upgrading to add.Next Fifteen Communications: Canaccord Genuity reduces target price from 120p to 94p downgrading from buy to hold.Persimmon: Liberum Capital takes target price from 1245p to 1261p, while its hold recommendation remains unaltered.Playtech: Investec places its target price (prev.: 630p) under review, while staying with its hold recommendation. Canaccord Genuity raises target price from 780p to 825p retaining its buy recommendation. Daniel Stewart increases target price from 790p to 840p and keeps its buy recommendation.Redrow: Liberum Capital ups target price from 241p to 304p and upgrades to buy.Regus: Investec downgrades from buy to add with a target price of 205p.Salamander Energy: RBC Capital cuts target price from 250p to 170p downgrading to neutral.Shire: Barclays increases target price from 2515p to 2800p, while its overweight rating is kept.Stagecoach: Investec places its target price (prev.: 325p) under review, while leaving its add rating unchanged.Standard Chartered: Goldman Sachs reduces target price from 1900p to 1700p leaving its neutral rating unaltered.Taylor Wimpey: Liberum Capital moves target price from 113p to 127p and keeps a buy recommendation.
More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.